Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015
- 852 Downloads
Since 2011, several direct oral anticoagulants (DOACs; dabigatran, rivaroxaban, apixaban) have been introduced as alternatives to warfarin for stroke prophylaxis in atrial fibrillation. We wanted to investigate changes in utilization of oral anticoagulants for atrial fibrillation in Norway following the introduction of DOACs.
Using nationwide registries, we identified all adults with pharmacy dispensings for warfarin or DOACs between January 2010 and December 2015 in Norway, and used ambulatory reimbursement codes to identify atrial fibrillation as indication. We defined incident use by a 1-year washout period. We describe trends in prevalent and incident use of warfarin and DOACs between 2010 and 2015, as well as patterns of treatment switching for incident users.
One hundred twenty-nine thousand two hundred eighty-five patients filled at least one prescription for an oral anticoagulant for atrial fibrillation; the yearly number of incident users increased from 262 to 421 per 100,000 person-years; and the yearly share of incident users who initiated a DOAC increased to 82%. Half the prevalent users were on a DOAC by 2015. Within a year of drug initiation, 6, 12, 16 and 20% of incident users of apixaban, rivaroxaban, warfarin and dabigatran, respectively, switched oral anticoagulant.
Use of DOACs for anticoagulation in atrial fibrillation became more prevalent between 2010 and 2015 in Norway, at the expense of warfarin.
KeywordsAtrial fibrillation Drug utilization Warfarin Dabigatran Rivaroxaban Apixaban
LJK and RS did the analyses. LJK wrote the manuscript. All authors helped plan and design the study, interpret findings and revise the manuscript. All authors approved the final version of the manuscript.
Compliance with ethical standards
The Regional Committee for Medical and Health Research Ethics in Central Norway approved the study protocol before the study commenced. The Norwegian Data Protection Authority gave a licence to link registry data.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Fuster V, Ryden LE, Asinger RW et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104(17):2118–2150PubMedGoogle Scholar
- 5.Angell MS, Tiwari S, Løchen ML (2015) Prevalens og risikofaktorer for selvrapportert atrieflimmer hos menn og kvinner - Tromsøundersøkelsen [Prevalence and risk factors for self-reported atrial fibrillation in men and women—the Tromsø study]. Hjerteforum 28(4):36–42 NorwegianGoogle Scholar
- 6.Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18):2370–2375. doi: 10.1001/jama.285.18.2370 CrossRefPubMedGoogle Scholar
- 15.Wallentin L, Yusuf S, Ezekowitz MD et al (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745):975–983. doi: 10.1016/S0140-6736(10)61194-4 CrossRefPubMedGoogle Scholar
- 17.Wallentin L, Lopes RD, Hanna M et al (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127(22):2166–2176. doi: 10.1161/CIRCULATIONAHA.112.142158 CrossRefPubMedGoogle Scholar
- 20.Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14(10):1385–1413. doi: 10.1093/europace/eus305 CrossRefPubMedGoogle Scholar
- 21.January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1–76. doi: 10.1016/j.jacc.2014.03.022 CrossRefPubMedGoogle Scholar
- 23.Norsk selskap for trombose og hemostase (2013) Retningslinjer for antitrombotisk behandling og profylakse [Norwegian Society of Thrombosis and Haemostasis (2013) Guidelines on antithrombotic therapy and prophylaxis]. MagicApp. https://www.magicapp.org/app#/guideline/1. Accessed 27 June 2017. Norwegian
- 24.O'Brien EC, Kim S, Hess PL, Kowey PR, Fonarow GC, Piccini JP, Peterson ED (2015) Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation. JAMA Intern Med 175(5):848–850. doi: 10.1001/jamainternmed.2015.13 CrossRefPubMedGoogle Scholar
- 26.Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 18(2):129–136Google Scholar
- 28.World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problem - 10th revisionGoogle Scholar
- 29.Wonca International Classification Committee (1998) International Classification of Primary Care - 2nd EditionGoogle Scholar
- 33.Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE (2014) Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 113(3):485–490. doi: 10.1016/j.amjcard.2013.10.035 CrossRefPubMedGoogle Scholar
- 39.Ramm J (2013) Eldres bruk av helse- og omsorgstjenester [Health and care. Use of services among the elderly]. Stat Anal 137:93–100 NorwegianGoogle Scholar